By Connor Hart
Five Below issued an upbeat outlook for its current fiscal year ahead as it posted a narrower-than-expected decline in comparable sales during its fiscal fourth quarter. The low-cost retailer's mid-2024 reset resulted in a better-than-expected end to the year, and momentum is expected to continue into its fiscal 2025. Same-store sales fell 3.0% in its recent quarter, better than the 3.3% decline expected by Wall Street. Shares rise 9.6%, to $82.88, in after-hours trading.
ProAssurance inked a roughly $1.3 billion deal to be bought by The Doctors Co. Under the agreement, ProAssurance's stockholders would receive $25 a share in cash, representing a roughly 60% premium to Wednesday's closing price. The deal is expected to close in the first half of 2026, pending approval by the specialty insurer's shareholders. Shares surge 51%, to $23.40, in post-market trading.
Akebia Therapeutics commenced an underwritten public offering. The biopharmaceutical company didn't say how many shares of its common stock it expects to sell, nor did it disclose anticipated proceeds. It said all shares are being offered by the company. Shares fall 21%, to $2.25, in after-hours trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
March 19, 2025 19:11 ET (23:11 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。